Abstract
Get full access to this article
View all access options for this article.
References
1.
FDA News release, September 15, 1997 .
2.
Rubin
LJ
. Pathology and pathophysiology of primary pulmonary hypertension . Am J Cardiol
1995 ; 75 (suppl ): 51 –4A .
3.
Bever
KA
Perry
PJ
. Dexfenfluramine hydrochloride: An anorexigenic agent . Am J Health-Syst Pharm
1997 ; 54 : 2059 –72 .
4.
D'Arcy
PF
. Warnings from the UK Committee on Safety of Medicines: Pulmonary hypertension with fenfluramine and dexfenfluramine . Int J Pharm
1992 ; 6 : 217 –8 .
5.
Connolly
HM
Crary
JL
McGoon
MD
Hensrud
PD
Edwards
RS
Edwards
WD
, Valvular heart disease associated with fenfluramine–phentermine . N Engl J Med
1997 ; 337 : 581 –8 .
6.
Robiolio
PA
Rigolin
VH
Wilson
JS
, Carcinoid heart disease: Correlation of high serotonin level with valvular abnormalities detected by cardiac catheterization and echocardiography . Circulation
1995 ; 92 : 790 –5 .
7.
Redfield
MM
Nicholson
WJ
Edwards
WD
, Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations . Ann Intern Med
1992 ; 117 : 50 –2 .
8.Package insert . Redux (dexfenfluramine) . Lexington, MA : Wyeth-Ayerst Company , April 1996 .
9.
Abenhaim
L
Moride
Y
Brenot
F
, Appetite-suppressant drugs and the risk of primary pulmonary hypertension . N Engl J Med
1996 ; 335 : 609 –16 .
10.
Lazowick
AL
Jamison
GW
. Dexfenfluramine for the treatment of obesity . Pharm Ther J
1996 ; 21 : 417 –21 .
11.
Lazowick
AL
Levin
GM
. Potential withdrawal syndrome associated with SSRI discontinuation . Ann Pharmacother
1995 ; 29 : 1284 –5 .
12.Discontinuation Consensus Panel . Antidepressant discontinuation syndrome: Update on serotonin reuptake inhibitors . J Clin Psychiatry
1997 ; 58 (suppl 7 ): 3 –40 .
13.
Oswald
I
Lewis
SA
Dunleavy
DLF
, Drugs of dependence though not of abuse: Fenfluramine and imipramine . Br Med J
1971 ; 3 : 70 –3 .
14.
Lejoyeux
M
Ades
J
Maurad
I
Solomon
J
Dilsaver
S
. Antidepressant withdrawal syndrome: Recognition, prevention and management . CNS Drugs
1996 ; 5 : 278 –92 .
15.
Otani
K
Tanaka
O
Kaneko
S
, Mechanisms of the development of trazodone withdrawal symptoms . Int Clin Psychopharmacol
1994 ; 9 : 131 –3 .
16.
Zajecka
J
Tracy
KA
Mitchell
S
. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review . J Clin Psychiatry
1997 ; 58 : 291 –7 .
17.
Coupland
NJ
Bell
CJ
Potokar
JP
. Serotonin reuptake inhibitor withdrawal . J Clin Psychopharmacol
1996 ; 16 : 356 –62 .
18.
Pinder
RM
Brogden
RN
Sawyer
PR
, Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity . Drugs
1975 ; 10 : 241 –323 .
19.
Steel
JM
Briggs
M
. Withdrawal depression in obese patients after fenfluramine treatment . Br Med J
1972 ; 3 : 26 –7 .
20.
Bowen
DJ
Spring
B
Fox
E
. Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy . J Behav Med
1991 ; 14 : 91 –110 .
21.
Akaoka
H
Aston-Jones
G
. Indirect serotonergic agonist attenuate neuronal opiate withdrawal . Neuroscience
1993 ; 54 : 561 –5 .
22.
Spring
B
Wurtman
J
Gleason
R
, Weight gain and withdrawal symptoms after smoking cessation: A preventive intervention using d-fenfluramine . Health Psychol
1991 ; 10 : 216 –23 .
23.
Nutt
DJ
Cowen
PJ
. Diazepam alters brain 5-HT function in man: Implications for the acute and chronic effects of benzodiazepines . Psychol Med
1987 ; 17 : 601 –7 .
24.
Tabakoff
B
Hoffman
PL
Moses
F
. Neurochemical correlates of ethanol withdrawal: Alterations in serotonergic function . J Pharm Pharmacol
1977 ; 29 : 471 –6 .
25.
Dilsaver
SC
Greden
JF
. Antidepressant withdrawal phenomena . Biol Psychiatry
1984 ; 19 : 237 –56 .